Nicotinamide adenine dinucleotide (NAD+) is a fundamental coenzyme and signaling molecule present in all living cells. Beyond its essential role in redox biochemistry as an electron carrier, NAD+ serves as a critical substrate for numerous enzymes that regulate cellular processes central to neurodegeneration. These include the sirtuin family of deacetylases, poly(ADP-ribose) polymerases (PARPs), CD38/CD157 ectoenzymes, and various metabolic enzymes. The declining NAD+ levels observed with normal aging and in neurodegenerative diseases represent a promising therapeutic target that has garnered significant research attention in recent years.
The discovery that NAD+ functions not only as a cofactor but also as a signaling molecule transformed our understanding of cellular regulation.[@lautrup2019] NAD+-dependent enzymes sense the metabolic state of the cell and respond by modifying protein function through post-translational modifications. This allows cells to adapt to changing energy demands, stress, and damage. The balance between NAD+ synthesis and consumption determines the activity of these enzymes, making NAD+ levels a rheostat for cellular health and longevity.
Nicotinamide adenine dinucleotide (NAD+) is a fundamental coenzyme and signaling molecule present in all living cells. Beyond its essential role in redox biochemistry as an electron carrier, NAD+ serves as a critical substrate for numerous enzymes that regulate cellular processes central to neurodegeneration. These include the sirtuin family of deacetylases, poly(ADP-ribose) polymerases (PARPs), CD38/CD157 ectoenzymes, and various metabolic enzymes. The declining NAD+ levels observed with normal aging and in neurodegenerative diseases represent a promising therapeutic target that has garnered significant research attention in recent years.
The discovery that NAD+ functions not only as a cofactor but also as a signaling molecule transformed our understanding of cellular regulation.[@lautrup2019] NAD+-dependent enzymes sense the metabolic state of the cell and respond by modifying protein function through post-translational modifications. This allows cells to adapt to changing energy demands, stress, and damage. The balance between NAD+ synthesis and consumption determines the activity of these enzymes, making NAD+ levels a rheostat for cellular health and longevity.
NAD+ levels decline substantially with age across multiple tissues, including the brain.[@hou2020] This decline is attributed to multiple factors including reduced biosynthesis, increased consumption by overactive enzymes, and impaired cellular uptake. The consequences are widespread, affecting mitochondrial function, DNA repair capacity, chromatin remodeling, and stress responses. This age-related NAD+ decline creates a permissive environment for neurodegenerative processes, making NAD+ repletion a potential intervention strategy.[@schondorf2018]
The kynurenine pathway serves as the primary de novo biosynthetic route for NAD+ in mammals. This pathway begins with the essential amino acid tryptophan and proceeds through multiple enzymatic steps to produce quinolinic acid, which is subsequently converted to NAD+ by quinolinic acid phosphoribosyltransferase (QAPRT). The key rate-limiting enzymes in this pathway are indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO), both of which are expressed in various tissues including the brain.
The complete de novo pathway proceeds as follows:
Tryptophan → N-formylkynurenine → Kynurenine → 3-hydroxyanthranilic acid → Quinolinic acid → NAD+
The salvage pathway is the predominant route for NAD+ biosynthesis in most mammalian tissues, including the brain. This pathway recycles nicotinamide, a byproduct of NAD+-consuming reactions, back into NAD+. The rate-limiting enzyme in this pathway is nicotinamide phosphoribosyltransferase (NAMPT), which converts nicotinamide to nicotinamide mononucleotide (NMN). NMN is then converted to NAD+ by nicotinamide mononucleotide adenylyl transferases (NMNATs).
| Enzyme | Function | Location |
|--------|----------|----------|
| NAMPT | Rate-limiting: converts nicotinamide to NMN | Cytosol |
| NMNAT1-3 | Converts NMN to NAD+ | Nucleus (NMNAT1), Cytosol (NMNAT2), Mitochondria (NMNAT3) |
| PARP1/2 | Consumes NAD+ in DNA repair | Nucleus |
| SIRT1-7 | NAD+-dependent deacetylases | Multiple compartments |
The Preiss-Handler pathway utilizes niacin (nicotinic acid) as a precursor. Niacin is converted to nicotinic acid mononucleotide (NAMN) by nicotinic acid phosphoribosyltransferase (NAPRT), then to NAD+ via NMNAT. This pathway is particularly important in the liver and kidney. While niacin supplementation has been explored, it causes flushing side effects that limit tolerability.
The sirtuin family comprises seven members (SIRT1-7) that depend on NAD+ for their deacetylase and ADP-ribosyltransferase activities. In the brain, SIRT1 and SIRT3 are particularly important. SIRT1 is primarily nuclear and regulates chromatin remodeling, gene expression, and synaptic plasticity. It deacetylates histone proteins and transcription factors including PGC-1α, FOXO, and p53. SIRT1 activity declines with age and in Alzheimer's disease, contributing to transcriptional dysregulation and impaired synaptic function.
SIRT3 is located in mitochondria where it deacetylates and regulates numerous metabolic enzymes. SIRT3 plays a critical role in mitochondrial function by deacetylating MnSOD (manganese superoxide dismutase) to enhance its antioxidant activity, and regulating mitochondrial DNA repair enzymes. Declining SIRT3 activity contributes to mitochondrial dysfunction and increased oxidative stress in neurodegenerative conditions.
PARP1 and PARP2 are activated by DNA damage and consume NAD+ to synthesize poly(ADP-ribose) polymers that facilitate DNA repair. While this function is essential, excessive PARP activation in chronic neurodegenerative conditions can deplete cellular NAD+ pools. In Alzheimer's disease, increased DNA damage and PARP activation create a vicious cycle where NAD+ depletion impairs the ability of sirtuins to protect neurons while DNA damage continues to accumulate. [berger2018 2018, NAD+ in DNA repair and cancer therapy](https://pubmed.ncbi.nlm.nih.gov/29398618/)
These ectoenzymes consume NAD+ to produce cyclic ADP-ribose (cADPR), a second messenger involved in calcium signaling. While their role in neurodegeneration is less well-characterized, they represent a significant sink for NAD+ turnover and may influence calcium homeostasis in neurons and glia. [harlan2016 2016, NAD+ metabolism in immune cell function](https://pubmed.ncbi.nlm.nih.gov/27213244/)
NAD+ is essential for mitochondrial respiration through its role in glycolysis and the TCA cycle as an electron carrier. More importantly, NAD+-dependent sirtuins regulate mitochondrial biogenesis, dynamics, and quality control. SIRT1 activates PGC-1α, the master regulator of mitochondrial biogenesis. Declining NAD+ levels impair this activation, resulting in reduced mitochondrial content and function in AD brains. SIRT3 maintains mitochondrial proteostasis by deacetylating proteins involved in fatty acid oxidation, amino acid metabolism, and antioxidant defense.
Neurons are particularly vulnerable to DNA damage due to their high metabolic activity and limited regenerative capacity. PARP1-mediated DNA repair consumes significant NAD+ pools. In AD, elevated DNA damage from oxidative stress, amyloid toxicity, and mitochondrial dysfunction leads to chronic PARP activation and NAD+ depletion. This creates a feedforward loop where impaired DNA repair leads to more damage, more PARP activation, and further NAD+ depletion. [berger2018 2018, NAD+ in DNA repair and cancer therapy](https://pubmed.ncbi.nlm.nih.gov/29398618/)
SIRT1 directly regulates tau phosphorylation through deacetylation of tau and by modulating the activity of glycogen synthase kinase-3β (GSK-3β). SIRT1 also influences amyloid precursor protein (APP) processing by regulating α-secretase activity, promoting the non-amyloidogenic pathway. Declining SIRT1 activity in AD may therefore contribute to both tau hyperphosphorylation and increased amyloid-β production.
NAD+ and sirtuins are essential for synaptic plasticity, the cellular basis of learning and memory. SIRT1 regulates the expression of synaptic proteins and dendritic spine formation. NAD+ also directly influences synaptic function through its role in calcium signaling and mitochondrial energy supply. The combined decline of NAD+ and SIRT1 activity in AD therefore contributes to synaptic dysfunction and cognitive decline.
Microglial NAD+ metabolism influences inflammatory responses. NAMPT expression is reduced in AD microglia, limiting their ability to maintain NAD+ levels and regulate inflammation. NAD+ can be released from cells and act as a signaling molecule that modulates immune cell function. The interplay between NAD+ metabolism and neuroinflammation in AD remains an active area of investigation. [gao2025 2025, NAMPT-mediated NAD+ biosynthesis in neuroinflammation](https://pubmed.ncbi.nlm.nih.gov/38651234/)
Parkinson's disease is strongly linked to mitochondrial dysfunction. The PINK1/Parkin pathway of mitophagy is regulated by NAD+-dependent signaling. NAD+ repletion enhances mitophagy and protects dopaminergic neurons against mitochondrial toxins. Studies in PD models show that NAD+ precursors can improve mitochondrial function and neuronal survival. [schondorf2018 2018, schondorf2018](https://pubmed.ncbi.nlm.nih.gov/28696412/)
NAD+ levels are reduced in PD brains and in multiple experimental models of PD. Dopaminergic neurons have particularly high energy demands, making them especially vulnerable to NAD+ decline and resulting ATP deficits. Restoration of NAD+ protects against MPTP and 6-OHDA toxicity in models, suggesting therapeutic potential.
NAD+ and sirtuins regulate α-synuclein aggregation and toxicity. SIRT2 inhibition has been shown to reduce α-synuclein toxicity in cellular and animal models. This provides a mechanistic link between NAD+ metabolism and the core pathological feature of PD. The interplay between sirtuin activity, α-synuclein aggregation, and neuronal survival represents an important therapeutic target.
Dopaminergic neurons require substantial ATP to maintain pacemaker activity and neurotransmitter release. The decline of NAD+ with age and in PD impairs mitochondrial ATP production, contributing to neuronal vulnerability. Enhancing NAD+ levels may therefore address the energy deficit that underlies PD pathogenesis.
NAD+ decline is observed in ALS models and patient tissues. NAD+ precursors including NMN and NR improve survival in SOD1 mouse models of ALS. The mechanisms likely involve improved mitochondrial function, reduced oxidative stress, and enhanced DNA repair. Clinical trials of NAD+ precursors in ALS are underway.
NAD+ depletion occurs in Huntington's disease models and patients. SIRT1 activity is impaired, contributing to transcriptional dysregulation through altered chromatin remodeling. NAD+ repletion improves outcomes in models through restoration of mitochondrial function and reduction of mutant huntingtin toxicity. Clinical trials are evaluating NAD+ precursors in HD. [bonkowski2016 2016, Slowing aging by NAD+ replenishment](https://pubmed.ncbi.nlm.nih.gov/27694994/)
NAD+ metabolism is altered in demyelinating diseases. Oligodendrocyte survival and remyelination require adequate NAD+ levels. NAD+ precursors may promote remyelination by enhancing oligodendrocyte function and reducing inflammation.
Several NAD+ precursors are under clinical investigation for neurodegenerative diseases:
| Compound | Mechanism | Clinical Status | Key Findings |
|----------|-----------|-----------------|--------------|
| Nicotinamide riboside (NR) | Salvage pathway | Phase I/II for AD | Safe, increases NAD+ levels in blood and brain |
| Nicotinamide mononucleotide (NMN) | Salvage pathway | Phase I for aging | Increases NAD+, may improve cognitive function |
| Nicotinamide (NAM) | Salvage pathway | Approved supplement | Well-tolerated but causes flushing |
| Niacin (NA) | Preiss-Handler | Approved | Increases NAD+ but causes vasodilation |
Sirtuin-activating compounds aim to enhance the beneficial effects of NAD+ without requiring NAD+ repletion:
| Compound | Target | Development Status | Evidence |
|----------|--------|-------------------|-----------|
| Resveratrol | SIRT1 | Clinical trials for AD | Mixed results; may require adequate NAD+ levels |
| SRT2104 | SIRT1 | Phase I completed | Enhanced mitochondrial function in models |
| SRT3025 | SIRT1 | Preclinical | Improved cognition in AD models |
PARP inhibitors could preserve NAD+ pools by reducing excessive consumption:
| Drug | Primary Use | Neurodegeneration Studies |
|------|-------------|---------------------------|
| Olaparib | Approved (cancer) | Preclinical: reduced DNA damage, improved memory |
| Rucaparib | Approved (cancer) | Preclinical: neuroprotective effects |
| PJ34 | Experimental | Preclinical: reduced PARP activation, improved outcomes |
The most effective therapeutic strategy may combine NAD+ repletion with sirtuin activation or PARP inhibition. This multi-target approach addresses multiple aspects of NAD+ metabolism simultaneously. Clinical trials evaluating combination therapies are planned.
Several challenges must be addressed for successful clinical translation:
The following diagram shows the key molecular relationships involving NAD+ Metabolism Pathway in Neurodegeneration discovered through SciDEX knowledge graph analysis: